Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
AUTOR(ES)
Araujo, F G
RESUMO
The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, significant survival rates resulted when the same dose of IL-12 was used in combination the same doses of atovaquone (P=0.01) or clindamycin (P=0.001). Infected mice treated with IL-12 plus drug produced significantly higher levels of gamma interferon than controls. Although IL-12 was effective only when administered before infection, these results suggest that this cytokine may be a useful adjunct in the therapy of human toxoplasmosis in situations when cysts reactivate and tachyzoites start multiplying in immunocompromised patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163683Documentos Relacionados
- Interleukin-12 enhances murine survival against acute toxoplasmosis.
- Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
- Synergistic Effect of Clindamycin and Atovaquone in Acute Murine Toxoplasmosis
- Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.
- Effect of Clindamycin on Acute and Chronic Toxoplasmosis in Mice
